MEDICUS PHARMA LTD. Foreign Currency Transaction Gain (Loss), before Tax
MEDICUS PHARMA LTD. (MDCX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$204.25 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-05-14
- MEDICUS PHARMA LTD. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$204.25K.
- MEDICUS PHARMA LTD. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$21.56K.
- MEDICUS PHARMA LTD. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $10.83K.
- MEDICUS PHARMA LTD. foreign currency transaction gain (loss), before tax for the quarter ending 2025-03-31 was $0.00.
- MEDICUS PHARMA LTD. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$10.73K.
- MEDICUS PHARMA LTD. foreign currency transaction gain (loss), before tax for fiscal 2024 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$204.25K 10-Q · filed 2026-05-14 | -$225.81K derived: sum of 2 quarters · filed 2026-05-14 | -$214.98K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2025-12-31 | -$21.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$10.73K derived: sum of 2 quarters · filed 2026-03-25 | -$10.73K 10-K · filed 2026-03-25 | |
| 2025-09-30 | $10.83K 10-Q · filed 2025-11-14 | $10.83K 10-Q · filed 2025-11-14 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |